Thermo Fisher Scientific (TMO) vs. Accelerate Diagnostics (AXDX) Head to Head Contrast

Thermo Fisher Scientific (NYSE: TMO) and Accelerate Diagnostics (NASDAQ:AXDX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Volatility and Risk

Thermo Fisher Scientific has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500.

Profitability

This table compares Thermo Fisher Scientific and Accelerate Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Thermo Fisher Scientific 11.73% 15.94% 7.41%
Accelerate Diagnostics -3,085.36% -60.99% -57.85%

Dividends

Thermo Fisher Scientific pays an annual dividend of $0.60 per share and has a dividend yield of 0.3%. Accelerate Diagnostics does not pay a dividend. Thermo Fisher Scientific pays out 10.2% of its earnings in the form of a dividend.

Valuation & Earnings

This table compares Thermo Fisher Scientific and Accelerate Diagnostics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Thermo Fisher Scientific $18.27 billion 3.99 $2.02 billion $5.89 30.90
Accelerate Diagnostics $250,000.00 6,038.60 -$66.37 million ($1.20) -22.71

Thermo Fisher Scientific has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

86.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 48.0% of Accelerate Diagnostics shares are owned by institutional investors. 0.5% of Thermo Fisher Scientific shares are owned by insiders. Comparatively, 50.0% of Accelerate Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Thermo Fisher Scientific and Accelerate Diagnostics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Thermo Fisher Scientific 0 1 14 0 2.93
Accelerate Diagnostics 0 0 2 0 3.00

Thermo Fisher Scientific currently has a consensus target price of $204.46, indicating a potential upside of 12.32%. Accelerate Diagnostics has a consensus target price of $33.00, indicating a potential upside of 21.10%. Given Accelerate Diagnostics’ stronger consensus rating and higher probable upside, analysts clearly believe Accelerate Diagnostics is more favorable than Thermo Fisher Scientific.

Summary

Thermo Fisher Scientific beats Accelerate Diagnostics on 9 of the 15 factors compared between the two stocks.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables. The Analytical Instruments segment provides a range of instruments, consumables, software and services. The Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. The Laboratory Products and Services segment offers controlled temperature technologies products, growth protection and separation products, and water and laboratory products.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply